| Date | Title | | | 09/02/10 | MediciNova to Present at the Rodman and Renshaw Annual Global Investment Conference| SAN DIEGO, Sep 2, 2010 (GlobeNewswire via COMTEX) --MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Shintaro Asako, Chief Financial Officer of MediciNova, will present a company overview at the Rodman and Renshaw Annual Global Investment Conference on Monday, September 13, 2010 at 3:40 p.m. Eastern time. The conference is being held at... |
|  | | 08/16/10 | MediciNova Reports Second Quarter 2010 Results| SAN DIEGO, Aug 16, 2010 (GlobeNewswire via COMTEX) --MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the second quarter ended June 30, 2010.
A detailed discussion of financial results and product development programs can be found in MediciNova's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, wh... |
| | | 07/12/10 | MediciNova Announces Estimated Timing of Payments to Former Avigen Stockholders| SAN DIEGO, Jul 12, 2010 (GlobeNewswire via COMTEX) --MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it expects to make an initial payment from the escrow account to the former stockholders of Avigen, Inc. by July 29, 2010.
Under the terms of the definitive Merger Agreement, former Avigen stockholders are due to receive as part of... |
| | | 07/07/10 | Insight on MediciNova's MN-166 Mechanism of Action Reported in Proceedings of the National Academy of Sciences| SAN DIEGO, Jul 7, 2010 (GlobeNewswire via COMTEX) --MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported that the June 22, 2010 issue of Proceedings of the National Academy of Sciences (PNAS) USA included an article related to the mechanism of action of MN-166 (ibudilast), as an emerging therapeutic for neurological disorders. The research was lead by Dr. E... |
| | | 07/06/10 | MediciNova Nets $9.5 Million From Settlement of Auction Rate Securities Held by UBS| SAN DIEGO, Jul 6, 2010 (GlobeNewswire via COMTEX) --MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that on July 1, 2010, it completed the sale of all of its Auction Rate Securities ("ARS") held by UBS AG at par value. After repaying the ARS Loan described below, MediciNova netted $9.5 million from the transaction, all of which has been inv... |
| | | 06/14/10 | MediciNova Appoints Michael Coffee as Chief Business Officer| SAN DIEGO, Jun 14, 2010 (GlobeNewswire via COMTEX) --MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Michael Coffee has joined MediciNova as its Chief Business Officer, reporting directly to Dr. Yuichi Iwaki, MediciNova's President and Chief Executive Officer.
Commenting on Mr. Coffee's employment, Dr. Iwaki said, "I am pleased to ann... |
| | | 05/17/10 | MediciNova Reports First Quarter 2010 Results| SAN DIEGO, May 17, 2010 (GlobeNewswire via COMTEX) --MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the first quarter ended March 31, 2010.
A detailed discussion of financial results and product development programs can be found in MediciNova's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, whic... |
| | | 05/11/10 | MediciNova Secures $15 Million Debt Facility From Oxford Finance Corporation| SAN DIEGO, May 11, 2010 (GlobeNewswire via COMTEX) --MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that it has entered into a $15 million senior secured term loan with Oxford Finance Corporation.
"This funding significantly strengthens our balance sheet and enables us to further support the clinical development of our lead compound, MN-... |
| | | 04/23/10 | MediciNova Releases Notice of Pendency and Settlement of Class Action| SAN DIEGO, Apr 23, 2010 (BUSINESS WIRE) --MediciNova, Inc., a biopharmaceutical company publicly traded on the
Nasdaq Global Market (NASDAQ: MNOV) and the Hercules Market of the Osaka
Securities Exchange (OSAKA: 4875), today releases the notice of pendency
and settlement of class action seen below:
SUPERIOR COURT FOR THE STATE OF CALIFORNIA
FOR THE COUNTY OF ALAMEDA
... |
| | | 04/01/10 | The Clinical Potential and Therapeutic Differentiation of MediciNova's MN-166 Featured in Neurology Articles| SAN DIEGO, Apr 1, 2010 (GlobeNewswire via COMTEX) --MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).
The primary publication, authored by Frederik Barkhof, M.D., Ph.D., ... |
| | | 03/24/10 | MediciNova Reports Fourth Quarter and Full Year 2009 Results| SAN DIEGO, Mar 24, 2010 (GlobeNewswire via COMTEX) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fourth quarter and full year ended December 31, 2009.
A detailed discussion of financial results and product development programs can be found in MediciNova's Annual Report on Form 10-K for the year ended December... |
| | | 03/17/10 | MediciNova Reports Positive Preliminary Results From a Phase Ib Clinical Trial of MN-221 in Moderate to Severe COPD Patients| SAN DIEGO, Mar 17, 2010 (GlobeNewswire via COMTEX) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today reported positive preliminary results from a Phase Ib clinical trial to evaluate the safety and efficacy of MN-221 in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD). There were no clinically significant safety c... |
| | | 02/01/10 | MediciNova Appoints Dr. Kirk Johnson Chief Scientific Officer| SAN DIEGO, Feb 1, 2010 (GlobeNewswire via COMTEX) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Kirk Johnson, Ph.D. has joined MediciNova as its Chief Scientific Officer, reporting directly to Dr. Yuichi Iwaki, MediciNova's President and Chief Executive Officer.
Commenting on Dr. Johnson's employment, Dr. Iwaki said, "I am pleased... |
| | | 01/05/10 | MediciNova Extends Conversion Deadline to January 11, 2010| SAN DIEGO, Jan 5, 2010 (GlobeNewswire via COMTEX) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that it has extended the deadline for submission of conversion notices for the first conversion date for its floating rate secured convertible notes due 2011 from December 31, 2009 to January 11, 2010.
At the closing of the acquisition of Av... |
| |
|
